Presentation- Massachusetts General Hospital: Vaccine and Immunotherapy Center 3916 The Vaccine and Immunotherapy Center (VIC) at Massachusetts General Hospital seeks to accelerate the development of innovative new technologies with broad applicability to the treatment and prevention of cancer and infectious diseases in the United States and beyond. Continue reading
Tag Archives: preclinical
Parios Regenerative Sciences, Inc. Licenses Exclusive Rights to Organic Nanotechnology for Skin Repair
CONCORD, Mass., Nov. 1, 2012 /PRNewswire/ — Parios Regenerative Sciences, Inc., a privately held medical device company specializing in the development of biomaterials for skin repair and regeneration, has entered into a comprehensive license agreement with Brown University, licensing exclusive rights to a proprietary organic nanotechnology for use in dermatological applications. The nanotechnology, Oderm, has clinical relevance in cosmetic skin rejuvenation, dermatological applications, and advanced wound care. Continue reading
RetroSense Therapeutics Completes pre-IND Meeting for RST-001
ANN ARBOR, Mich.–(BUSINESS WIRE)– RetroSense Therapeutics, a gene therapy company dedicated to vision restoration, announced completion of a pre-IND meeting with the Center for Biological Evaluation and Research (CBER) division of the FDA that took place on May 22nd 2012 regarding RetroSenses lead biologic, RST-001 for vision restoration in retinal degenerative conditions. The purpose of the meeting was to obtain CBERs guidance for the clinical path to a Biologics License Application (BLA) for RST-001 in the US, and clarity on the steps required for Investigational New Drug (IND) submission. The discussions included manufacturing criteria, the scope and design of the preclinical studies, and the scope and design of Phase I and IIa clinical trials Continue reading